27 October 2025 As we enter a new era of drug discovery, where IND authorization can now be granted based on human data only, marking a clean departure from mandatory animal testing, Qureator's human organ-on-chip platform has laid the groundwork for the world’s first IND approval of its kind. The IND grant concerns SillaJen's BAL0891-tislelizumab combination therapy to treat solid tumors. Qureator's patient-derived vascularized tumor immune microenvironment (TME) model h